DIAGENS-B (02526.HK): Three-Year Pact with Yongjiang Lab on Imaging AI
- The three-year strategic agreement covers training, optimisation, validation and demonstration of medical imaging models in Guangxi.
- The parties will use the iMedImage® foundation model and promote results from Guangxi nationwide.
NewTimeSpace News: On 6 November 2026, Hangzhou Diagens Biotechnology Co., Ltd. (Stock Code: 2526) announced a three-year strategic cooperation agreement with Yongjiang Laboratory, a digital-intelligence platform in Guangxi, to advance training, optimisation, validation and demonstration of medical imaging models.
The announcement shows that the parties will use the laboratory's regional coordination to connect clinical and insurance scenarios at hospitals of different levels in Guangxi, combining the Group's iMedImage® foundation model and smart products for training, multi-centre validation and demonstration. Results at flagship hospitals and regional alliances will be promoted nationwide, and Guangxi's proximity to ASEAN will be tapped for technology cooperation and exports. The board sees the pact enriching validation conditions and accelerating commercialisation; specific projects need separate contracts and ethics clearance.
- HK Stock Connect Insight | DIAGENS-B (02526.HK): 778,962 options and RSUs granted, southbound holding ratio rises to 0.52%
- DIAGENS-B (02526.HK): Signs Three-Year Cooperation Framework Agreement with Anzhen'er on Provincial Medical Imaging AI Platform
- DIAGENS-B(02526.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 55.88 million, loss widened by 4070.37% YoY
- Diagens-B (02526.HK): Core Product AI AutoVision® Obtains NMPA Class III Medical Device Registration Certificate
- NewTimeSpace | Diagens (02526.HK) Stock Price Triples Two Weeks After Listing; Net Losses and Competitive Risks Coexist Under High Valuation
